An interventional study of Inosine pranobex in Lymphatic Disease and HIV Infections, sponsored by Newport Pharmaceuticals International. Completed at 1 site in United States. Open to male participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2005-06-24.
Sponsored by Newport Pharmaceuticals International · Not applicable, Interventional, and Treatment
Among 53 studies in Lymphatic Diseases with a site in United States — 8 open to participants now, 17 under way, 1 of them phase 3. Lymphatic Diseases · United States.
Among the 53 studies in Lymphatic Diseases with a site in United States, this one is one of 7 with no phase, and was the 1st registered.
83 studies on the registry are indexed under Lymphatic Diseases; 12 are open to participants now.
Browse Lymphatic Diseases studies →8 of the 53 studies in Lymphatic Diseases with a site in United States are open now. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Czechia, Italy and 3 more countries
Ages 18–130
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · Sites in United States
Ages 1 days–100 yrs · Healthy volunteers
Novartis Pharmaceuticals · Sites in United States, France, Italy and 4 more countries
Ages 18+
Curis, Inc. · Sites in United States, Czechia, France and 4 more countries
Ages 18+
Masonic Cancer Center, University of Minnesota · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 9 Lymphatic Diseases studies recruiting now, 6 set no upper age limit and none stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 50 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 26 · Phase 3 4 · Phase 4 1
First in 2003; this study’s year is marked.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 48 across the 42 interventional studies, 742 across the 6 observational. Of the 34 that completed or were terminated, 18 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 53 have an industry lead sponsor. The 10 most frequent:
Newport Pharmaceuticals International is the lead sponsor of 6 studies on the registry; none are open to participants now.
Newport Pharmaceuticals International has 3 studies filed under Lymphatic Diseases — fewer than ten, so there is no comparison to draw.
5 of the studies in Lymphatic Diseases with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04529772Phase 3Acerta Pharma BVA Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) | 2027-02-22 |
| NCT06001385Center for International Blood and Marrow Transplant ResearchHLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis | 2026-12-24 |
| NCT01451502Masonic Cancer Center, University of MinnesotaInfusion of Cell Populations From Unlicensed Umbilical Cord Blood Units | 2027-01 |
| NCT03328078Curis, Inc.CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL) | 2027-07 |
| NCT03162536ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) | 2027-09-17 |
Add all 5 to your calendar (.ics) → With an account.
Among the 53 studies in Lymphatic Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this Phase III, randomized, double-blind, placebo-controlled study in patients with immunologic deficiency is to determine the effect of Isoprinosine in producing an immuno-restorative response within the study observation period (including the 2-month period following cessation of the 28 days of treatment), measured by one or more of the following immunological parameters:
Exclusion Criteria
Co-existing Condition:
Patients with the following are excluded:
Patients with the following are excluded:
Prior Medication:
Excluded:
Prior Treatment:
Excluded:
Patients who have unexplained immunodepression and are at risk of developing AIDS.
IV drug abuse.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This study is completed, as verified in Jun 1989. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Inosine Pranobex
Newport Pharmaceuticals International